- Moderna Inc (NASDAQ:MRNA) announced an agreement with the United Kingdom government to establish an mRNA Innovation and Technology Center in the U.K.
- Additionally, Moderna plans to expand its presence in the U.K. through investments in R&D activities.
- Moderna is collaborating with the National Institute for Health Research on a Phase 3 study investigating Moderna's bivalent Omicron-containing booster candidate (mRNA-1273.214) in the U.K.
- Moderna expects its manufacturing facility to produce mRNA vaccines, including vaccines against COVID-19, seasonal influenza, respiratory syncytial virus (RSV), and potential other vaccines, with the collaboration of the U.K. government.
- Separately, the U.K. government purchased 60 million doses of Moderna's COVID-19 vaccine, which may include authorized booster vaccine candidates for delivery in 2022 and 2023.
- CNBC reports that the facility is expected to start producing shots in 2025, and Britain has committed to buy Moderna's vaccines for the next decade under the agreement.
- Moderna Chief Executive Stephane Bancel said he aimed for a variant-specific booster to be ready by August, ahead of Britain's planned autumn booster campaign, CNBC added.
- Price Action: MRNA shares are down 1.51% at $128.03 during the premarket session on the last check Wednesday.
- Photo by mufidpwt via Pixaby
